Evaluating the multitargeted potency of Pixuvri against cell cycle regulation proteins in cervical cancer.

ABSTRACT: Cervical cancer, primarily caused by persistent infection with high-risk human papillomavirus strains, leads to abnormal cell growth in the cervix. Globally, it accounts for over 600,000 new cases and 340,000 deaths annually, with the highest burden in low- and middle-income countries due to limited screening and vaccination. Early detection is challenging as initial stages are asymptomatic, while advanced cases are challenging to treat. Current options, including surgery, radiotherapy, and chemotherapy, face issues like toxicity, limited efficacy, recurrence, and drug resistance caused by tumor heterogeneity and adaptive mechanisms. Multitargeted drug design offers a solution by modulating multiple cancer pathways, enhancing efficacy, minimizing resistance, and reducing side effects. In t

SUBMITTER: Alshehri MA 

PROVIDER: S-EPMC12163068 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature